Compositions and methods for the treatment of cancer

Details Compositions and methods for the treatment of cancer Compositions and methods for the treatment of cancer

2001-05-14

2008-10-14

Lewis, Patrick T (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S023000, C514S025000, C544S060000, C544S125000, C544S361000, C546S048000

Reexamination Certificate

active

07435726

ABSTRACT:
This invention relates to compositions comprising thalidomide and another anti-cancer drug which can be used in the treatment or prevention of cancer. Preferred anti-cancer drugs are topoisomerase inhibitors. A particular composition comprises thalidomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, and irinotecan. The invention also relates to methods of treating or preventing cancer which comprise the administration of a thalidomide and another anti-cancer drug to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of chemotherapy or radiation therapy which comprise the administration of thalidomide to a patient in need of such reduction or avoidance.

REFERENCES:
patent: 4604463 (1986-08-01), Miyasaka et al.
patent: 5385901 (1995-01-01), Kaplan et al.
patent: 5593990 (1997-01-01), D'Amato
patent: 5622959 (1997-04-01), Priel et al.
patent: 5629327 (1997-05-01), D'Amato
patent: 5643915 (1997-07-01), Andrulis, Jr. et al.
patent: 5654312 (1997-08-01), Andrulis, Jr. et al.
patent: 5712291 (1998-01-01), D'Amato
patent: WO 94/20085 (1994-09-01), None
Marx et al. Proc. Am. Soc. Clin. Onocology (1999), vol. 18, p. 454a.
Pitot et al. Journal of Clinical Onocology (1997), vol. 15, pp. 2910-2919.
Hecht, Jr. Oncology (1998), 12(8 Suppl. 6): 72-8 (Abstract).
Houghton et al. Cancer Chemother Pharmacol (1995), vol. 36, pp. 393-403.
Avgeropoulos et al.,The Oncologist4:209-224 (1999).
Bach et al.,Acta Pathol. Microbiol. Scand.59:491-499 (1963).
Bach et al.,The Lancet71:1271 (1963).
Braun et al.,Biochem. Biophys. Res. Comm.98(4):1029-1034 (1981).
Chaundry et al.,Cancer Res.26:1884-1886 (1966).
Costa et al.,Blood92 (10:suppl. 1):235b (1998).
Cunningham et al.,The Lancet352(9138):1413-1418 (1998).
D'Amato et al.,Proc. Natl. Acad. Sci.91:4082-4085 (1994).
De et al.,J. Pharm. Sci.64(2):262-266 (1975).
DiPaolo et al.,Proc. Soc. Exp. Biol. And Med.114:384-387 (1963).
DiPaolo et al.,ScienceJun. 26, 1964:1583 (1964).
DiPaolo et al.,Cancer Chemo. Reports29:99-102 (1963).
Ehrenpreis et al.,Gastroenterology117:1271-1277 (1999).
Gershbein,Riv. Pathol. Nerv. Ment.87(4):88-92 (1966).
Grabstald et al.,Clin. Pharmacol. And Ther.6(3):298-302 (1965).
Hatfill et al.,Leuk. Res.15(2-3):129-136 (1991).
Koch,Prog. Med. Chem.22:165-242 (1985).
Lenicque,Acta Zool.48:128-139 (1967).
Marx et al.,Proc. Am. Soc. Clin. Oncology18:454a (1999).
McCann,Drug Topics41-42 (Jun. 21, 1999).
McHugh et al.,Clin. Exper. Immunol., 99:160-167 (1995).
Miura et al.,Experientia26:305-306 (1970).
Mohri et al.,Chem. Pharm. Bull.16:2289-2292 (1968).
Moller et al.,J. Immunol.159:5157-5161 (1997).
Moreira et al.,J. Expr. Med.177:1675-1680 (1993).
Muckter,Antimicrobial Agents and Chemotherapy531-538 (1965).
Mummery et al.,Toxicol. Lett.18(3):201-209 (1983).
Olson et al.,Clin. Pharmacol. And Ther.6:293-297 (1965).
Physician's Desk Reference, 2412-2418 (54thed., 2000).
Physician's Desk Reference, 911-916 (54thed., 2000).
Pitot et al.,J. Clin. Oncology15(8):2910-2919 (1997).
Robbins et al.,Basic Pathology, 2nded., W.B. Saunsers Co., Philadelphia, pp. 68-79 (1976).
Roe et al.,Nature200:1016-1017 (1963).
Rothenberg,Annals of Oncology8:837-855 (1997).
Rothenberg et al.,Cancer85(4):786-795 (1999).
Rothenberg et al.,J. Clin. Oncology14(4):1128-1135 (1996).
Singhal et al.,New England J. Med.341(21):1565-1571 (1999).
Sugiura et al.,GANN55:57-60 (1964).
Vasiliauskas et al.,Gastroenterology117:1278-1287 (1999).
Villa et al.,Haematol. Latina6:217-221 (1963).
Villa et al.,The Lancet, Mar. 30, 1963, 725 (1963).
Woodyatt,The Lancet, Apr. 7, 1962, 750 (1962).
Zwart,Arzneim-Forsch.16(12):1688-1689 (1966).
R. Govindarajan et al.,Lancet(North American Edition), 2000, vol. 356, No. 9229, pp. 566-567.
Cao et al.British Journal of Cancer80:716-723 (1999).
Burton et al.,Current Opinion in Oncology, 11(3): 157-161 (1999).
Cheston et al.,Seminars in Oncology, 27(5): 560-577 (2000).
Mundle et al.,Blood, 96(11): 146a (2000).
Bioworld Today, Nov. 4, 2005, p. 2.
Hecht, J.R., “Gastrointestinal Toxicity of Irinotecan,”Oncology, 12(8 Suppl. 6): 72-8 (1998).

Affiliated with

Also associated with

Rating

Compositions and methods for the treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for the treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the treatment of cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4019692